Diagonal Bio AB (publ) (DIABIO.ST)
SEK 0.02
(4.18%)
SEK 0.02
(4.18%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 28.5 Million SEK | -16.22% |
| 2022 | 34.02 Million SEK | -5.5% |
| 2021 | 36 Million SEK | 261.06% |
| 2020 | 9.97 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 29.36 Million SEK | -5.36% |
| 2024 Q1 | 28.51 Million SEK | 0.03% |
| 2024 Q2 | 31.02 Million SEK | 8.8% |
| 2023 FY | 28.5 Million SEK | -16.22% |
| 2023 Q4 | 28.5 Million SEK | -6.45% |
| 2023 Q3 | 30.47 Million SEK | 6.68% |
| 2023 Q2 | 28.56 Million SEK | -9.28% |
| 2023 Q1 | 31.48 Million SEK | -7.46% |
| 2022 FY | 34.02 Million SEK | -5.5% |
| 2022 Q4 | 34.02 Million SEK | 14.29% |
| 2022 Q3 | 29.77 Million SEK | -11.74% |
| 2022 Q2 | 33.73 Million SEK | 3.15% |
| 2022 Q1 | 32.7 Million SEK | -9.18% |
| 2021 Q1 | 9.48 Million SEK | -4.86% |
| 2021 FY | 36 Million SEK | 261.06% |
| 2021 Q3 | 39.04 Million SEK | 134.52% |
| 2021 Q2 | 16.64 Million SEK | 75.47% |
| 2021 Q4 | 36 Million SEK | -7.78% |
| 2020 Q4 | 9.97 Million SEK | 0.0% |
| 2020 FY | 9.97 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 75.932% |
| Ziccum AB (publ) | 14.97 Million SEK | -90.409% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -42.248% |
| BioArctic AB (publ) | 1.18 Billion SEK | 97.596% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | 54.297% |
| Mendus AB (publ) | 755.95 Million SEK | 96.229% |
| Genovis AB (publ.) | 288.85 Million SEK | 90.131% |
| Intervacc AB (publ) | 259.61 Million SEK | 89.019% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | 32.057% |
| Active Biotech AB (publ) | 44 Million SEK | 35.209% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 89.773% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | 54.132% |
| Aptahem AB (publ) | 63.02 Million SEK | 54.767% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 94.255% |
| Kancera AB (publ) | 65.64 Million SEK | 56.571% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 91.886% |
| Fluicell AB (publ) | 9.34 Million SEK | -205.225% |
| Saniona AB (publ) | 64.14 Million SEK | 55.556% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | 15.16% |
| Biovica International AB (publ) | 131.4 Million SEK | 78.306% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | 46.196% |
| AcouSort AB (publ) | 34.51 Million SEK | 17.399% |
| Xintela AB (publ) | 18.39 Million SEK | -54.977% |
| Abliva AB (publ) | 87.49 Million SEK | 67.419% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 96.25% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 97.735% |
| OncoZenge AB (publ) | 20.34 Million SEK | -40.157% |
| Amniotics AB (publ) | 26.08 Million SEK | -9.285% |
| 2cureX AB (publ) | 16.62 Million SEK | -71.477% |
| CombiGene AB (publ) | 120.61 Million SEK | 76.364% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -369.113% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 98.5% |
| Camurus AB (publ) | 1.9 Billion SEK | 98.506% |
| Corline Biomedical AB | 100.1 Million SEK | 71.522% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 83.905% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 79.724% |
| I-Tech AB | 152.44 Million SEK | 81.299% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 97.2% |
| Cyxone AB (publ) | 43.65 Million SEK | 34.697% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 63.773% |
| Biosergen AB | 7.2 Million SEK | -295.889% |
| Cantargia AB (publ) | 223.71 Million SEK | 87.257% |
| NextCell Pharma AB | 81.28 Million SEK | 64.93% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 96.275% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | 5.518% |
| Nanologica AB (publ) | 77.42 Million SEK | 63.182% |
| SynAct Pharma AB | 228.01 Million SEK | 87.498% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -6.52% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -31.356% |
| LIDDS AB (publ) | 17.65 Million SEK | -61.473% |
| Lipum AB (publ) | 12.11 Million SEK | -135.409% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 97.964% |
| Alzinova AB (publ) | 123.18 Million SEK | 76.858% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 88.041% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -237.173% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 66.551% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -91.728% |
| Simris Alg AB (publ) | 174.55 Million SEK | 83.668% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 86.865% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 95.638% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 67.259% |